From the Radiology Department (A.S., S.S.).
Neurosurgery Department (K.M.), UH St Ivan Rilski, Sofia, Bulgaria.
AJNR Am J Neuroradiol. 2020 Apr;41(4):681-686. doi: 10.3174/ajnr.A6453. Epub 2020 Mar 12.
Conventional nonadhesive liquid embolic agents currently are the criterion standard for endovascular embolization of cerebral AVMs. However, inadequate distal penetration into the nidus and unstable proximal plug formation are the major limitations of this approach and of the currently available embolic materials. The aim of this study was to evaluate the hypothetic efficacy of combining liquid embolic agents with different properties and viscosities for use in endovascular embolization of cerebral AVMs.
From March 2018 to March 2019, sixteen patients with cerebral AVMs (12 women, 4 men; age range, 33-61 years) underwent endovascular embolization with combined liquid embolic agents delivered serially via a single microcatheter. The procedure consists of initial embolization with PHIL 30%, followed by Menox 18 through the same microcatheter. According to the Spetzler-Martin scale, 11 (68.75%) AVMs were grades I-II, 4 (25%) were grade III, and 1 (6.25%) was grade IV. Angiographic, technical, and clinical outcomes were analyzed independently.
Combined PHIL and Menox embolization through the same microcatheter via 21 pedicles was performed in these 16 patients. Once the length of the reflux reached approximately 2 cm, PHIL 30% was switched to Menox 18. Antegrade flow and distal penetration of the serially applied liquid embolic agents were observed in all 16 cases. The ability to completely control the flow of the materials and avoid any dangerous proximal reflux was noted in all performed embolizations. The estimated average size reduction of the treated AVMs was 85%, ranging from 50% to 100%. Complete embolization was achieved in 10/16 or 62.5% of the cases. There was no procedure-related complication during or after the embolization. No mortality or postprocedural clinical worsening was seen. Clinical success and complete obliteration were confirmed with at least 1 follow-up angiography in 10/16 patients.
Serial delivery of nonadhesive liquid embolic agents via the same microcatheter was safe and effective in our study and may be a potential technique for routine AVM treatment. However, further investigations are required to validate the safety and the efficacy of the method.
传统的非黏附性液体栓塞剂目前是脑动静脉畸形血管内栓塞的标准方法。然而,这种方法和目前可用的栓塞材料的主要局限性是远端不能充分渗透到病灶内,近端栓塞栓不稳定。本研究的目的是评估将具有不同特性和粘度的液体栓塞剂联合用于脑动静脉畸形血管内栓塞的理论疗效。
从 2018 年 3 月至 2019 年 3 月,16 例脑动静脉畸形患者(12 例女性,4 例男性;年龄 33-61 岁)接受了通过单个微导管连续输送联合液体栓塞剂的血管内栓塞治疗。该程序包括最初用 PHIL 30%进行栓塞,然后通过相同的微导管输送 Menox 18。根据 Spetzler-Martin 分级,11 例(68.75%)动静脉畸形为Ⅰ-Ⅱ级,4 例(25%)为Ⅲ级,1 例(6.25%)为Ⅳ级。分别分析了血管造影、技术和临床结果。
通过同一条微导管的 21 个分支对 16 例患者进行了联合 PHIL 和 Menox 栓塞。一旦回流长度达到约 2cm,就将 PHIL 30%切换为 Menox 18。在所有 16 例患者中均观察到顺行流动和串行应用的液体栓塞剂的远端渗透。在所有进行的栓塞中,都能够完全控制材料的流动并避免任何危险的近端回流。治疗后,估计动静脉畸形的平均缩小率为 85%,范围为 50%-100%。10/16 或 62.5%的病例完全栓塞。栓塞过程中或之后没有与手术相关的并发症。无死亡或术后临床恶化。在 10/16 例患者中,至少有 1 次随访血管造影证实了临床成功和完全闭塞。
通过同一条微导管连续输送非黏附性液体栓塞剂在本研究中是安全有效的,可能是常规动静脉畸形治疗的一种潜在技术。然而,需要进一步的研究来验证该方法的安全性和疗效。